Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Vivani Medical, Inc.VANI · healthcare
GradeNonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $39.4M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, thin data, degenerate inputsnot computable: distress, fortress balance sheet
Inputs computable5 of 14
Graded fromfilings received through Mar 26, 2026197 days before the rescan; every figure keyed to the SEC receipt date
Last close$1.222026-10-08; market equity $110.0M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$1$1.5NovDecJanFebMarAprMayJunJulAugSepOct$1.23
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2016nonen/aQ2
Mar 21, 2019nonen/aQ1
Mar 21, 2020nonen/aQ2
Mar 21, 2021nonen/aQ1
Apr 21, 2022nonen/aQ2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 26, 2026; the document on sec.gov.

Vivani Medical, Inc. (“Vivani,” the “Company,” “we,” “us,” “our” or similar terms) is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal™ technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 42.9%[3-4]
Thin data. 5 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 59.0
Gross profitabilitynot computable32.2%
latest aligned inputs end 2021-12-31; latest annual assets end 2025-12-31
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(5.7%)[1,5-7](6.6%)59.08112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 4
Solvency, sleeve percentile 64.3
Twelve-month failure probabilitynot computable0.07%
latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime(14.41)[1,8-13](0.31)68.97562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio2.71x[8-9]2.96x59.88392025-12-31
Growth and financing, sleeve percentile 70.1
Revenue growth, three-year compoundnot computable10.0%
four consecutive annual observations are required
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
required facts have no common fiscal period end
Asset growth, three years(8.3%)[1,7,14-15]2.1%66.17042025-12-31
Net share issuance, one year42.9%[3-4]2.5%74.16342026-03-25

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(1.4%)8.0%45hotter than 45 of 100 peers
Distance from 52-week high(34.2%)(31.4%)45closer to its high than 45 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(23.0%)(1.0%)21pricier than 79 of 100 peers
Book value to price0.170.2837pricier than 63 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five years245.4%20.3%93more equity-funded than 93 of 100 peers
Relative strength against the sector, log excess return(0.23)(0.14)45ahead of 45 of 100 peers

Inputs: market equity $111.0M; EBIT -$27.6M; free cash flow -$25.5M; book equity $19.0M; sales $0; cash $19.9M[16].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(64.0%)✗ fail[5,7]
Operating cash flow above zero-$24.3M✗ fail[6]
Return on assets improved(12.7 pts)✗ fail[5,7,14,17]
Operating cash flow exceeds net income$2.3M✓ pass[5-6]
Long-term leverage felln/a[1,7,14]
Current ratio improved(70.4 pts)✗ fail[8-9,18-19]
No new shares issued42.9%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improved0.0 pts✗ fail[2,7,14,20]
Cash, filings, liquidity
Cash and equivalents$19.9M[21]
Operating cash flow, four quarters-$25.3M[6,21-25]
Months of runway9.4
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing57
10-Q received Aug 13, 2026
Median daily dollar volume$240,741
63 sessions
Days since newest grade input197

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$39.4M2025-12-312026-03-2610-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax$02025-12-312026-03-2610-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding84,647,8032026-03-252026-03-2610-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding59,242,9032025-03-282025-03-3110-Kfiling · viewer · series
5net incomeus-gaap:NetIncomeLoss-$26.6M2025-12-312026-03-2610-Kfiling · viewer · series
6operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$24.3M2025-12-312026-03-2610-Kfiling · viewer · series
7assetsus-gaap:Assets$41.6M2024-12-312026-03-2610-Kfiling · viewer · series
8current assetsus-gaap:AssetsCurrent$17.9M2025-12-312026-03-2610-Kfiling · viewer · series
9current liabilitiesus-gaap:LiabilitiesCurrent$6.6M2025-12-312026-03-2610-Kfiling · viewer · series
10retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$148.5M2025-12-312026-03-2610-Kfiling · viewer · series
11operating incomeus-gaap:OperatingIncomeLoss-$27.6M2025-12-312026-03-2610-Kfiling · viewer · series
12book equityus-gaap:StockholdersEquity$15.7M2025-12-312026-03-2610-Kfiling · viewer · series
13liabilitiesus-gaap:Liabilities$23.7M2025-12-312026-03-2610-Kfiling · viewer · series
14assetsus-gaap:Assets$45.8M2023-12-312025-03-3110-Kfiling · viewer · series
15assetsus-gaap:Assets$51.1M2022-12-312024-03-2610-Kfiling · viewer · series
16shares outstandingdei:EntityCommonStockSharesOutstanding90,203,3562026-08-132026-08-1310-Qfiling · viewer · series
17net incomeus-gaap:NetIncomeLoss-$23.5M2024-12-312026-03-2610-Kfiling · viewer · series
18current assetsus-gaap:AssetsCurrent$20.4M2024-12-312026-03-2610-Kfiling · viewer · series
19current liabilitiesus-gaap:LiabilitiesCurrent$6.0M2024-12-312026-03-2610-Kfiling · viewer · series
20revenueus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax$02024-12-312025-03-3110-Kfiling · viewer · series
21cashus-gaap:CashAndCashEquivalentsAtCarryingValue$19.9M2026-06-302026-08-1310-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$12.2M2026-06-302026-08-1310-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$6.2M2026-03-312026-05-1310-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$17.6M2025-09-302025-11-1310-Qfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$11.2M2025-06-302026-08-1310-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.